Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Centre Hospitalier Regional Et Universitaire De Brest

Verified siteinfo

France Boulevard Tanguy Prigent, 29200 Brest, France

  • 260 trials recruiting
  • Non-small cell lung cancer · Gastric cancer · Oesophageal adenocarcinoma
  • Adults and children

About Specializations

Centre Hospitalier Regional Et Universitaire De Brest in Brest, France specialises in clinical trials of conditions such as Non-small cell lung cancer, Gastric cancer, Oesophageal adenocarcinoma, Sjogren's syndrome, and other specialisations. This site conducts important research.

Main research areas of the site

Neoplasms Research

At Centre Hospitalier Regional Et Universitaire De Brest, clinical research in oncology is focused on improving care for people with Triple Negative Breast Cancer, especially those with residual disease after initial treatment. The studies are designed to better understand whether adding or adjusting treatment after surgery can improve outcomes for patients with this aggressive cancer type.

  • Evaluating new treatment strategies for Triple Negative Breast Cancer
  • Assessing the benefit of additional therapy after surgery in patients with residual disease
  • Studying ways to improve invasive disease-free survival and long-term cancer control

This work reflects a strong focus on cancer treatment effectiveness and post-operative care within the hospital’s Institut de cancérologie et d'hématologie.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Site location
Boulevard Tanguy Prigent29200 BrestFrance
Open in maps ↗
Recruiting now
260 trials
Conditions studied
339
Partner status
Verified site

More sites in BrestFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

558 clinical trials

Sjogren's syndrome

Recruiting

Phase 3 Randomized, Double‑Blind Study of Telitacicept versus Placebo for Efficacy and Safety in Adults with Active Primary Sjögren’s Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Telitacicept
  • Sponsor:Vor Biopharma Inc.

Immunisation+3

Recruiting

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
  • Sponsor:Sanofi Vaccines US Inc.

Pancreatic carcinoma metastatic

Recruiting

Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atebimetinib
  • Sponsor:Immuneering Corp.

Chronic obstructive pulmonary disease

Recruiting

Study of Brenipatide (LY3537031) in Adults with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:LY3537031
  • Sponsor:Eli Lilly & Co.

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Recruiting
Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Focal segmental glomerulosclerosis

Recruiting

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Boehringer Ingelheim Espana S.A.

Asthma

Recruiting

A Study of Brenipatide Compared to Placebo for Adults with Uncontrolled Moderate to Severe Asthma

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:LY3537031
  • Sponsor:Eli Lilly & Co.

Cachexia

Recruiting

A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Visugromab
  • Sponsor:CatalYm GmbH

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.